Cardiff Oncology, Inc. (CRDF) Tops Q1 EPS by 3c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q1 EPS of ($0.22), $0.03 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $205 thousand versus the consensus estimate of $16.67 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Ennis (EBF) Reports In-Line Q1 EPS
• Bristow Group to acquire Berry Aviation for $105 million